Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,946.40
(
0.67%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
95.16
(
0.15%
)
Bitcoin
78,061.28
(
2.27%
)
News Focus
News Focus
Post# of 517475
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Hosai

Send PM Follow Ignore
Followers 20
Posts 1038
Boards Moderated 0
Alias Born 12/02/2023

Hosai

Re: Investor2014 post# 480567

Thursday, 01/16/2025 4:37:55 PM

Thursday, January 16, 2025 4:37:55 PM

Post# of 517475
Well in terms of that silly topic why do you think Donnanemab does not have the same EMA indication wording Blarcamesine has of "Treatment of Alzheimers disease and dementia" and instead has "To slow disease progression in adult patients with Alzheimer disease".

Both descriptions were added for the first time today as previouly Donnaemabs EMA indication each month for 2024 has always simply said "psychoanaleptics".
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News